Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy

Leukemia and Lymphoma

Volumn 51, Issue 8, 2010, Pages 1478-1484

  Bashir, Qaiser ^a   De Lima, Marcos J ^a   McMannis, John D ^a   Garcia Manero, Guillermo ^b   Shpall, Elizabeth ^a   Kantarjian, Hagop ^b   Cortes, Jorge E ^b   O'Brien, Susan M ^b   Jones, Dan ^b   Qazilbash, Muzaffar ^a   Wei, Wei ^a   Giralt, Sergio A ^a   Champlin, Richard E ^a   Hosing, Chitra ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Department of Leukemia ^*  (United States)

Author keywords

CML; hematopoietic progenitor cell; imatinib

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CD34 ANTIGEN; CYTARABINE; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CD34 SELECTION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE COUNT; MALE; PATIENT SAFETY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STEM CELL MOBILIZATION; TREATMENT WITHDRAWAL;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; FEASIBILITY STUDIES; FEMALE; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKAPHERESIS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77955447196     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2010.501534     Document Type: Article

References (30)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164-172.
2. Barrett J. Allogeneic stem cell transplantation for chronic myeloid leukemia. Semin Hematol 2003;40:59-71.
3. McGlave PB, De Fabritiis P, Deisseroth A, et al. Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 1994;343:1486-1488.
4. Hoyle C, Gray R, Goldman J. Autografting for patients with CML in chronic phase: an update. Hammersmith BMT Team LRF Centre for Adult Leukaemia. Br J Haematol 1994;86:76-81.
5. Deisseroth AB, Zu Z, Claxton D, et al. Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83:3068-3076.
6. Barnett MJ, Eaves CJ, Phillips GL, et al. Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study. Blood 1994;84:724-732.
7. Carella AM, Lerma E, Corsetti MT, et al. Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 1999;93:1534-1539.
8. Verfaillie CM,MillerWJ, Boylan K, McGlave PB. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992;79:1003-1010.
9. Kreuzer KA, Kluhs C, Baskaynak G, Movassaghi K, Dorken B, le Coutre P. Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging. Br J Haematol 2004;124:195-199.
10. Gordon MK, Sher D, Karrison T, et al. Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products. Leuk Lymphoma 2008;49:531-537.
11. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008;111:1774-1780.
12. BaccaraniM, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27: 6041-6051.
13. Selvaggi KJ, Wilson JW, Mills LE, et al. Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibodypurged bone marrow. Blood 1994;83:1698-1705.
14. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11: 3425-3432.
15. Kantarjian HM, Talpaz M, Giles F, O'Brien S, Cortes J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006;145:913-923.
16. Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007;109:58-60.
17. Olavarria E. Autologous stem cell transplantation in chronic myeloid leukemia. Semin Hematol 2007;44:252-258.
18. Gratwohl A, Baldomero H, Schwendener A, et al. The EBMT activity survey 2008 impact of team size, team density and new trends. Bone Marrow Transplant 2010 Mar29. [Epub ahead of print].
19. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006; 37:439-449.
20. Olavarria E, Parker S, Craddock C, et al. Collection of Phnegative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colonystimulating factor mobilization. Haematologica 2000;85:647- 652.
21. Archimbaud E, Michallet M, Philip I, et al. Granulocyte colony-stimulating factor given in addition to interferon-alpha to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia. Br J Haematol 1997;99:678-684.
22. Hernandez-Boluda JC, Carreras E, Cervantes F, et al. Collection of Philadelphia-negative stem cells using recombinant human granulocyte colony-stimulating factor in chronic myeloid leukemia patients treated with alpha-interferon. Haematologica 2002;87:17-22.
23. Michallet M, Thiebaut A, Philip I, et al. Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-alpha. Leukemia 2000;14:2064-2069.
24. Russo D, Martinelli G, Montefusco V, Amabile M, Rosti G, Marin L. Collection of Ph-negative progenitor cells from Ph+ CML patients in complete cytogenetic remission after longterm interferon-alpha therapy. Haematologica 1999;84:953- 935.
25. Reiffers J, Taylor K, Gluckman E, et al. Collection of Ph-negative progenitor cells with granulocyte-colony stimulating factor in patients with chronic myeloid leukaemia who respond to recombinant alpha-interferon. Br J Haematol 1998;102: 639-646.
26. Hui CH, Goh KY, White D, et al. Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia 2003;17:821-828.
27. Perseghin P, Gambacorti-Passerini C, Tornaghi L, et al. Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. Transfusion 2005;45:1214- 1220.
28. Drummond MW, Marin D, Clark RE, Byrne JL, Holyoake TL, Lennard A. Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. Br J Haematol 2003;123:479-483.
29. Vokurka S, Koza V, Lysak D, et al. Successful peripheral blood stem cells collection in imatinib pretreated and nilotinib-treated chronic myeloid leukemia patient. J Oncol 2010;2010:460859.
30. Hui CH, Hughes TP. Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the bench. Leuk Lymphoma 2006;47:1721-1723.